Drug search by name

Cozaar and Renal/liver disease

Result of checking the interaction of drug Cozaar and disease Renal/liver disease for safety when used together.

Check result:

Cozaar <> Renal/liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Losartan is converted in the liver to an active carboxylic acid metabolite and several inactive metabolites, and both parent drug and metabolites are eliminated by the kidney (35%) as well as by biliary excretion (60%). Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision. In patients with cirrhosis, however, significantly increased plasma concentrations of parent drug and active metabolite have been reported. Therapy with losartan should be initiated cautiously at a reduced dosage (50%) in patients with impaired liver function.

References:

Sachinidis A, Ko Y, Weisser P, Meyer zu Brickwedde MK, Dusing R, Christian R, Wieczorek AJ, Vetter H "EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells." J Hypertens 11 (1993): 155-62
Sica DA, Lo MW, Shaw WC, Keane WF, Gehr TWB, Halstenson CE, Lipschutz K, Furtek CI, Ritter MA, Shahinfar S "The pharmacokinetics of losartan in renal insufficiency." J Hypertens 13 Suppl (1995): s49-52
Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE "Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease." J Hypertens Suppl 12 (1994): s37-42
Furtek CI, Lo MW "Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography." J Chromatogr 573 (1992): 295-301
Lo MW, Goldberg MR, Mccrea JB, Lu H, Furtek CI, Bjornsson TD "Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans." Clin Pharmacol Ther 58 (1995): 641-9
Ishizaki H, Ohtawa M "Inhibitory effect of the nonpeptide angiotensin II receptor antagonist losartan and its active metabolite, E-3174, on cAMP phosphodiesterase: additional action of the antagonists." Biochem Pharmacol 48 (1994): 201-4
Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M "Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans." Br J Clin Pharmacol 35 (1993): 290-7
"Product Information. Cozaar (losartan)." Merck & Co, Inc, West Point, PA.
Christ DD, Wong PC, Wong YN, Hart SD, Quon CY, Lam GN "The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog." J Pharmacol Exp Ther 268 (1994): 1199-205

Cozaar

Generic Name: losartan

Brand Name: Cozaar

Synonyms: n.a.

What is Cozaar?